ArticleOncology letters2018
Butyrate upregulates the TLR4 expression and the phosphorylation of MAPKs and NK-κB in colon cancer cell
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Gut microbiota-metabolism axis in digestive tumors: Emerging targets for novel therapies (Review).Experimental and therapeutic medicine · 2026Review
- Infection-driven gut dysbiosis and epigenetic programming of microglia: toward a systems level framework linking microbial metabolites, neuroinflammation, synaptic dysfunction, and probiotic modulation.Frontiers in cellular and infection microbiology · 2026Review
- The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention.Gut microbes · 2025Review
- Comparative effects of dietary sodium butyrate and tributyrin on broiler chickens' performance, gene expression, intestinal histomorphometry, blood indices, and litter.Scientific reports · 2025Article
- Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling.Cell communication and signaling : CCS · 2025Review
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes.Frontiers in microbiology · 2025Review
- Energy metabolism and the intestinal barrier: implications for understanding and managing intestinal diseases.Frontiers in microbiology · 2025Review
- Disentangling the molecular mystery of tumour-microbiota interactions: Microbial metabolites.Clinical and translational medicine · 2024Review
- The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment.Molecules (Basel, Switzerland) · 2024Review
- IL-6 promotes tumor growth through immune evasion but is dispensable for cachexia.EMBO reports · 2024Article
- Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach.International journal of molecular sciences · 2024Review
- The functional roles of short chain fatty acids as postbiotics in human gut: future perspectives.Food science and biotechnology · 2024Review
- Modulative effect ofChinese herbal medicines · 2023Article
- Cathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-κB-NLRP3 signaling.Immunity, inflammation and disease · 2023Article
- Probiotic-Derived Bioactive Compounds in Colorectal Cancer Treatment.Microorganisms · 2023Review
- A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Regulation of short-chain fatty acids in the immune system.Frontiers in immunology · 2023Review
- Implication of gut microbes and its metabolites in colorectal cancer.Journal of cancer research and clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbiota and its induced inflammation in colorectal mucosa have been considered risk factors for the development of colorectal carcinogenesis. Previous studies demonstrated that the coexisting elements of microbiota in the gut, such as short chain fatty acids (SCFAs) and lipopolysaccharides (LPS), which exhibited regulatory effects on the intestinal epithelial cells individually. Unfortunately, the association between butyrate and the toll-like receptor (TLR) signaling pathway in the development of colon cancer is not fully elucidated. In the present study, by culturing human colon cancer SW480 cells or mouse colon cancer CT26 cells with butyrate and/or TLR4 ligand LPS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.